TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04316286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tele-multidisciplinary care
Description: Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
Study: NCT03860844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or equivalent
Description: Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin (nonliposomal)
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT01822366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused Cognitive Behavioral Therapy
Study: NCT03860844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim or equivalent
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase (PEG) Asparaginase
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L - Asparginase
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Pharmaceutical form: Solution for injection Route of administration: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L - Asparaginase (Erwinase)
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study: NCT02505269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study: NCT03028532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomid
Description: Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
Study: NCT04494984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INM005
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
Study: NCT03465137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM)
Description: Exposure-focused cognitive behavioral therapy
Study: NCT01480791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren vs. hydrochlorothiazide
Description: Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
Study: NCT00726310

Intervention type: DEVICE
Intervention: SpineLink® , SpineLink® II
Description: Spine plate system for lumbar spinal fusions
Study: NCT03687827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
Study: NCT04539665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended mesenteric resection.
Description: Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
Study: NCT02949687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ileal interposition with sleeve and sympathectomy
Description: laparoscopic ileal interposition with sleeve and sympathectomy
Study: NCT05979558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine with dexmedetomidine
Description: this group received with ropivacaine with dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine with placebo
Description: this group received with ropivacaine with normal saline
Study: NCT00946699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 0.1 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.3 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 1.0 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 3.0 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 10.0 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02725710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 600mg Gabapentin administered orally 1-2 hours prior to procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
Study: NCT02866773

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD4: Education sessions
Description: The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD4: Education sessions
Description: The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD4: Education sessions
Description: The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD4: Education sessions
Description: The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.
Study: NCT04429074

Intervention type: PROCEDURE
Intervention: Minimally invasive distal pancreatectomy
Description: Minimally invasive distal pancreatectomy

Intervention type: PROCEDURE
Intervention: Minimally invasive distal pancreatectomy
Description: Minimally invasive distal pancreatectomy
Study: NCT03456050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRC exercise
Description: The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
Study: NCT02283372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation
Study: NCT02497053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed/platinum chemotherapy
Description: Four cycles of pemetrexed/platinum chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/platinum chemotherapy
Description: Six cycles of pemetrexed/platinum chemotherapy
Study: NCT03793790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning with partial reinforcement
Description: Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
Study: NCT03456050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
Study: NCT01802931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK239512
Description: H3 receptor antagonist, potential victim of drug-drug interaction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK239512
Description: H3 receptor antagonist, potential victim of drug-drug interaction
Study: NCT01802931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole
Description: CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
Study: NCT02654730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal
Description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal
Description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
Study: NCT00108615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scans
Description: To measure changes in adipose tissue volumes

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scans
Description: To measure changes in adipose tissue volumes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: To detect a change in glucose tolerance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: To detect a change in glucose tolerance
Study: NCT03583112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine Hydrochloride Tablet
Description: oral one dapoxetine hydrochloride tablet before MRI scan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: oral one placebo tablet before MRI scan.
Study: NCT00655239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games
Description: The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
Study: NCT03231228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 1 g Infusion
Description: 1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 2 g Infusion
Description: 2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
Study: NCT00469040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M for 14 days
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M for 14 days
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M for 14 days
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M for 14 days
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M for 14 days
Description: M salt
Study: NCT05010395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention
Study: NCT03139435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Tomography
Description: Undergo peripheral nerve ultrasound
Study: NCT02812394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 (Dose Level 1)
Description: All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 (Dose Level 2)
Description: All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
Study: NCT00024206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orantinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02072733

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive geriatric assessment
Description: Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
Study: NCT06343129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary education program
Description: Jumpstart educational program:~https://www.rochesterlifestylemedicine.com/about-community-jumpstart/
Study: NCT02896751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed NIV mask
Description: use of 3D printed mask
Study: NCT02365506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablets administered orally in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablets administered orally in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match tablets administered orally in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match tablets administered orally in a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match tablets administered orally in a single dose
Study: NCT01174940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extracorporeal photopheresis
Description: Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient.